# Hims & Hers Health (HIMS) — InvestMoat Analysis

_Last analyzed: May 2026_
_Asset class: equity · Canonical page: https://investmoat.com/stocks/hims_

## Scores

| Dimension | Score (0–100) |
| --- | --- |
| Moat durability | 47 |
| Growth trajectory | 81 |
| Valuation | 55 |
| **Composite** | **59** |
| **Recommendation** | **Avoid** |

Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes.

## Key stats

- **Ticker:** HIMS
- **Market Cap:** ~$11B

## Moat

DTC telehealth subscription brand with vertical pharmacy and personalised compounded prescriptions — narrow brand moat, expanding clinical footprint, real regulatory tail risk.

### The DTC Telehealth Brand Moat

Hims's moat is **brand recognition + vertical pharmacy operations** in telehealth subscription — real but narrow, with regulatory exposure to compounded GLP-1 fluctuations:

- **DTC Brand Reach in Targeted Categories:** Hims has built genuine brand awareness in men's hair loss, sexual health, mental health, weight-loss, and women's hormonal health. The marketing flywheel and CAC-LTV economics in these categories are durable in normal market conditions, with subscriber retention in established categories averaging 12+ months.
- **Vertical Pharmacy and Compounding Operations:** Hims operates its own 503A/503B-style compounding pharmacies, allowing personalised GLP-1 and dermatology formulations. The April 2025 FDA shortage delisting forced compounded semaglutide off the market, but Hims has pivoted to oral GLP-1 personalisation and licensed Wegovy distribution — narrower but legal channel.
- **Clinical Network Scale:** Hims contracts with a national network of providers, allowing rapid intake-to-prescription on a single subscription stack. Switching costs for the patient are low but the convenience-and-pricing UX advantage vs traditional telehealth is real.

**Moat verdict:** Hims is a brand-and-bundle moat business in a regulated industry — AI is neutral-to-positive on cost (provider productivity) but the dominant moat questions are regulatory and competitive. The thesis is execution-and-category-expansion, not durable franchise economics, appropriately sized as speculative growth.

## Growth

FY26 revenue guide $2.4-2.5B (+45-50% YoY); subscribers ~3M. Weight-loss category remains the swing factor — branded Wegovy distribution licence + oral GLP-1 personalisation are growing but at lower margin than 2024 compounded semaglutide. New categories (testosterone, women's health) extend the platform.

- **Revenue CAGR estimate:** 30-45%
- **Primary type:** TAM expansion
- **Margin trend:** compressing
- **Key risk (high):** If FDA enforcement against personalised compounding tightens further or state regulators impose telehealth-prescription restrictions on GLP-1 in 2026-27, the weight-loss category could decline 30-40% and the margin profile compresses materially.
- **Drivers:**
  - Weight-Loss Category — Branded Wegovy + oral GLP-1; revenue growing but mix margin lower than 2024 (stable)
  - Subscriber Growth — +800K subscribers FY26; CAC payback <12 months in established categories (accelerating)
  - New Category Expansion — Women's health, testosterone, longevity adding incremental cohorts (accelerating)
- **Score derivation:** Base 90 (>30% CAGR hypergrowth) + 3 platform extension (women's health, testosterone, weight-loss next-gen) - 7 regulatory/category risk (compounded GLP-1 ban, ongoing FTC/state-AG scrutiny) - 6 margin compression (branded GLP-1 lower margin than compounded) = 80

## Valuation

At ~$50 HIMS trades at ~50× FY26 EPS — a hypergrowth multiple that prices in continued execution and expanding categories. Volatility around regulatory news cycles is high; the multiple has shown 40%+ drawdowns multiple times.

| Multiple | Value | Note |
| --- | --- | --- |
| Forward P/E (FY26) | ~50× | EPS ~$1.00 mid; growth-stock multiple |
| Forward P/E (FY27) | ~32× | Assumes 50% EPS growth on subscriber + category |
| Price / Sales (FY26) | ~4.5× | Premium vs Tele/DTC peers |
| PEG Ratio | ~1.1× | Fair on growth, none on regulatory risk |
| FCF Yield | ~3% | FCF building as capex moderates |

Valuation discounts none of the regulatory or category-shift risk; the equity is a high-volatility growth-and-execution position rather than a quality compounder. _(as of May 2026)_

## Price scenarios

### Bear — $28

FDA compounding enforcement tightens further, weight-loss category declines, multiple compresses to 20-25× on growth deceleration.

- FDA or state AG enforcement restricts personalised GLP-1 telehealth prescribing
- Branded Wegovy distribution disappoints on margin and subscriber retention
- Subscriber growth slows below 25% YoY as marketing CAC rises

### Base — $70

FY26 revenue $2.5B at high end, subscriber growth +35%, EBITDA margin expands to 14%, multiple holds at 35×.

- Subscriber base reaches 3.5M end-FY26
- Weight-loss category settles into branded + oral mix at sustainable margin
- New categories (women's health, testosterone) reach 15%+ of revenue

### Bull — $110

Hims becomes the dominant DTC chronic-care platform, EBITDA margin expands toward 20%, multiple sustains 40×+ on durable growth.

- Subscriber base exceeds 4.5M with NRR >115%
- International expansion (UK, Canada, EU pilot) materialises in 2026-27
- Platform category mix diversifies the regulatory tail-risk concentration

---

InvestMoat is an open-source research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.